ID   RPCI-WM1/IR
AC   CVCL_VJ33
DR   cancercelllines; CVCL_VJ33
DR   Cosmic; 2645647
DR   Wikidata; Q98129163
RX   PubMed=28548645;
CC   Selected for resistance to: ChEBI; CHEBI_76612; Ibrutinib (Imbruvica).
CC   Sequence variation: Mutation; HGNC; HGNC:7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C80307; Waldenstrom macroglobulinemia
DI   ORDO; Orphanet_33226; Waldenstrom macroglobulinemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M087 ! RPCI-WM1
SX   Female
AG   48Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 19-12-24; Version: 11
//
RX   PubMed=28548645; DOI=10.1038/bcj.2017.40; PMCID=PMC5518884;
RA   Paulus A., Akhtar S., Yousaf H.M., Manna A., Paulus S.M., Bashir Y.,
RA   Caulfield T.R., Blake M.K.K., Chitta K.S., Wang X., Asmann Y.,
RA   Hudec R., Springer W., Ailawadhi S., Chanan-Khan A.A.;
RT   "Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or
RT   CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through
RT   upregulation of Bcl-2 and AKT resulting in vulnerability towards
RT   venetoclax or MK2206 treatment.";
RL   Blood Cancer J. 7:e565.1-e565.11(2017).
//